Skip to main content

Table 1 Baseline characteristics of the overall population and subgroups of interest by dose received during the DBTP

From: Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials

  Acute headache medication users at baseline Users of migraine-specific medicine at baseline Non-users of migraine-specific medicine at baseline
Episodic migraine
  Placebo
(N = 315)
70 mg
(N = 305)
140 mg
(N = 312)
Placebo
(N = 191)
70 mg
(N = 179)
140 mg
(N = 192)
Placebo
(N = 124)
70 mg
(N = 126)
140 mg
(N = 120)
Demographics          
Age, years (range) 41.3 ± 11.2
(18–65)
41.2 ± 11.2
(18–63)
40.4 ± 11.1
(19–65)
43.3 ± 10.9
(18–65)
43.8 ± 11
(18–63)
42 ± 10.7
(19–65)
38.4 ± 11
(18–64)
37.5 ± 10.6
(19–63)
37.9 ± 11.4
(19–62)
Female, n (%) 271 (86.0) 261 (85.6) 266 (85.3) 164 (85.9) 152 (84.9) 169 (88) 107 (86.3) 109 (86.5) 97 (80.8)
Caucasian, n (%) 274 (87.0) 274 (89.8) 288 (92.3) 180 (94.2) 173 (96.6) 184 (95.8) 94 (75.8) 101 (80.2) 104 (86.7)
Baseline characteristics          
Monthly migraine days 8.3 ± 2.5 8.3 ± 2.5 8.3 ± 2.5 8.5 ± 2.5 8.4 ± 2.5 8.5 ± 2.4 7.9 ± 2.5 8.0 ± 2.3 8.1 ± 2.5
Monthly headache days 9.3 ± 2.6 9.0 ± 2.6 9.3 ± 2.5 9.3 ± 2.6 9.0 ± 2.6 9.3 ± 2.5 9.3 ± 2.6 9.0 ± 2.6 9.2 ± 2.6
Monthly migraine-specific medication days 3.5 ± 3.4 3.3 ± 3.4 3.5 ± 3.5 5.7 ± 2.6 5.7 ± 2.5 5.7 ± 2.7 0 0 0
Age at migraine onset 21.2 ± 10.1 21.2 ± 11 20.7 ± 9.9 20.6 ± 10.2 21.5 ± 11.4 21.2 ± 9.8 22.0 ± 10 20.7 ± 10.5 20.0 ± 10.2
Disease duration, years 20.2 ± 12.2 20.1 ± 12.2 19.8 ± 12.3 22.7 ± 11.9 22.4 ± 12.1 20.9 ± 12.2 16.4 ± 11.5 16.8 ± 11.5 18.0 ± 12.3
Acute headache medication use, n (%)          
Any 315 (100) 305 (100) 312 (100) 191 (100) 179 (100) 192 (100) 124 (100.0) 126 (100.0) 120 (100.0)
Migraine-specific 191 (60.6) 179 (58.7) 192 (61.5) 191 (100) 179 (100) 192 (100) 0 (0) 0 (0) 0 (0)
Non-migraine-specific 244 (77.5) 242 (79.3) 256 (82.1) 120 (62.8) 116 (64.8) 136 (70.8) 124 (100.0) 126 (100.0) 120 (100.0)
Migraine-preventive medication use, n (%)          
Naïve 174 (55.2) 164 (53.8) 184 (59.0) 84 (44) 73 (40.8) 87 (45.3) 90 (72.6) 91 (72.2) 97 (80.8)
Previous 131 (41.6) 132 (43.3) 120 (38.5) 100 (52.4) 100 (55.9) 100 (52.1) 31 (25.0) 32 (25.4) 20 (16.7)
History of treatment failure of preventive medication* 127 (40.3) 126 (41.3) 112 (35.9) 98 (54.7) 98 (54.7) 92 (47.9) 28 (22.6) 28 (22.2) 20 (16.7)
History of migraine with aura, n (%) 160 (50.8) 162 (53.1) 157 (50.3) 82 (42.9) 82 (45.8) 84 (43.8) 78 (62.9) 80 (63.5) 73 (60.8)
Chronic migraine
  Placebo
(N = 282)
70 mg
(N = 191)
140 mg
(N = 188)
Placebo
(N = 225)
70 mg
(N = 143)
140 mg
(N = 149)
Placebo
(N = 57)
70 mg
(N = 48)
140 mg
(N = 39)
Demographics          
Age, years (range) 42.2 ± 11.3 (18–66) 41.4 ± 11.3 (18–64) 43.1 ± 11 (18–64) 43.4 ± 11.1 (18–66) 42.5 ± 11 (18–64) 44.4 ± 10.3 (18–64) 37.7 ± 11 (18–64) 38.1 ± 11.7 (18–58) 38.3 ± 12.3 (20–58)
Female, n (%) 223 (79.1) 166 (86.9) 158 (84) 175 (77.8) 126 (88.1) 134 (89.9) 48 (84.2) 40 (83.3) 24 (61.5)
Caucasian, n (%) 264 (93.6) 176 (92.1) 182 (96.8) 215 (95.6) 134 (93.7) 146 (98) 49 (86) 42 (87.5) 36 (92.3)
Baseline characteristics          
Monthly migraine days 18.2 ± 4.7 17.9 ± 4.4 17.7 ± 4.6 18.2 ± 4.6 18.1 ± 4.4 17.7 ± 4.3 18.1 ± 5.3 17.1 ± 4.4 17.5 ± 5.9
Monthly headache days 21.1 ± 3.9 20.5 ± 3.8 20.7 ± 3.8 20.9 ± 3.8 20.6 ± 3.8 20.3 ± 3.7 21.8 ± 4.3 20.3 ± 4 21.9 ± 3.8
Monthly migraine-specific medication days 9.6 ± 7.6 8.8 ± 7.2 9.8 ± 7.0 12.0 ± 6.5 11.7 ± 5.8 12.3 ± 5.5 0 0 0
Age at migraine onset 20.3 ± 10.0 21.1 ± 10.5 21.5 ± 10.7 20.7 ± 10.1 19.9 ± 10.2 21.1 ± 10.8 18.8 ± 9.4 24.7 ± 10.9 23.2 ± 10.4
Disease duration, years 22.4 ± 12.6 20.7 ± 12.8 22.1 ± 11.8 23.1 ± 12.8 23.0 ± 12.9 23.8 ± 11.2 19.4 ± 11.7 13.9 ± 10.2 15.6 ± 11.9
Acute headache medication use, n (%)          
Any 282 (100) 191 (100) 188 (100) 225 (100) 143 (100) 149 (100) 57 (100) 48 (100) 39 (100)
Migraine-specific 225 (79.8) 143 (74.9) 149 (79.3) 225 (100) 143 (100) 149 (100) 0 (0) 0 (0) 0 (0)
Non-migraine-specific 246 (87.2) 167 (87.4) 161 (85.6) 189 (84) 119 (83.2) 122 (81.9) 57 (100) 48 (100) 39 (100)
Migraine-preventive medication use, n (%)          
Naïve 67 (23.8) 53 (27.7) 54 (28.7) 41 (18.2) 31 (21.7) 31 (20.8) 26 (45.6) 22 (45.8) 23 (59.0)
Previous 215 (76.2) 138 (72.3) 134 (71.3) 184 (81.8) 112 (78.3) 118 (79.2) 31 (54.4) 26 (54.2) 16 (41.0)
History of treatment failure of preventive medicationa 198 (70.2) 127 (66.5) 124 (66) 170 (75.6) 105 (93.8) 111 (94.1) 28 (49.1) 22 (45.8) 13 (33.3)
History of migraine with aura, n (%) 122 (43.3) 81 (42.4) 70 (37.2) 93 (41.3) 58 (40.6) 61 (40.9) 29 (50.9) 23 (47.9) 9 (23.1)
  1. a≥1 failed preventive medication
  2. Plus–minus values are means ± SD. Data in the table are for the full analysis set (all patients who underwent randomization)